4224 Campus Point Court
Suite 210
San Diego, CA 92121
United States
858 202 6300
https://www.regulusrx.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 30
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Joseph P. Hagan M.B.A. | CEO & Director | 958,23k | N/D | 1969 |
Ms. Crispina Calsada CPA | Chief Financial Officer | 579,3k | N/D | 1970 |
Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary | 575,94k | N/D | 1961 |
Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | N/D | N/D | 1969 |
Mr. Daniel J. Penksa | VP of Finance & Controller | N/D | N/D | 1986 |
Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | N/D | N/D | N/D |
Dr. Rekha Garg M.D., M.S. | Senior Vice President of Clinical Development & Regulatory | N/D | N/D | N/D |
Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | N/D | N/D | N/D |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Regulus Therapeutics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.